about
The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective surveyChanges in nutritional status after liver transplantationMELDNa score is associated with psychopathology and reduced quality of life in cirrhotic patients with a liver transplant perspective.Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry.Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement.Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts.An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial.Increased risk of cognitive impairment in cirrhotic patients with bacterial infections.Graft macrosteatosis and time of T-tube removal as risk factors for biliary strictures after liver transplantation.Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study.A low muscle mass increases mortality in compensated cirrhotic patients with sepsis.The multidisciplinary support in preventing alcohol relapse after liver transplantation: A single-center experience.Donor-to-recipient gender match in liver transplantation: A systematic review and meta-analysis.Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patientsIschemic Damage Represents the Main Risk Factor for Biliary Stricture After Liver Transplantation: A Follow-Up Study in a Danish PopulationAlbumin infusion in cirrhotic patients with infections other than spontaneous bacterial peritonitis: End of the story?Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients.May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?The Effect of 12 Weeks of β-Hydroxy-β-Methyl-Butyrate Supplementation after Liver Transplantation: A Pilot Randomized Controlled StudyThe additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver diseaseThe modification of quantity and quality of muscle mass improves the cognitive impairment after TIPSHepatic Encephalopathy and Sarcopenia: Two Faces of the Same Metabolic AlterationMuscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver CirrhosisPrevalence and impact of sarcopenia in non-cirrhotic portal hypertensionSarcopenic obesity in fatty liverSarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt
P50
Q28547409-A825B924-E6F2-4AA4-BD2F-80261222CBEDQ34067831-4E0DB915-AC30-4F1F-AA21-D41FBABBD246Q38843237-453C75D5-A20E-4430-A11D-3387A620C11FQ39062869-C863C748-A3EB-4236-89AE-81BBFB0C8926Q39212291-EC46B234-15EE-4C90-818C-EA0B27D751F7Q40607871-2F602FD5-9EC2-4529-A411-787E9BC5FB4BQ40925226-9B2AD017-5761-437A-8718-5E6B5C865911Q42269672-89BC0211-6FC0-4B70-90F5-666DBF732825Q45952333-B83B165C-68F3-413B-AA7E-CEB82CE9F860Q48260788-B322B3AC-8556-485D-A295-D1D0854C3E2CQ50092781-E56379ED-8343-400D-AB8D-2B1AA742AAEFQ54249394-805522AD-5A15-4525-ABF9-01AE4A4C2390Q55332957-2DA29529-A06A-421D-B7BE-F605F51E03BEQ57180186-3BAA23F9-266F-450F-9FBA-AFB19B2E70C4Q57787330-B4BF22D5-3E25-4E4E-B44A-44860FCA5967Q60198870-58E8100B-A1A6-46F1-8EC9-787FAE6C7277Q64880524-21ADA933-072D-4D4A-9965-4E033A5439CBQ88298478-E608DECD-C098-49D6-A50E-667349EB2947Q90227233-A446ECAC-437E-40E8-8B45-F77007A22810Q90637056-685D3AD5-E812-4823-8DF8-5EE0ED37E2BEQ91154885-ACA5B0E9-C802-4A8D-8E59-9CABB8E60A08Q91598157-C9CD90B7-71E4-4134-B3FE-7D12A8220FBCQ91639818-28709B22-EB21-4985-AEA0-F8779489AC3FQ92453872-CCC8C113-A35F-46B0-AC83-3B019B469CC1Q92503209-8414F64E-57FA-44AF-BA07-D7FED8008669Q92791553-DAAF404B-7E58-431E-89CE-E94A0621677E
P50
description
researcher ORCID ID = 0000-0003-2685-6504
@en
wetenschapper
@nl
name
Barbara Lattanzi
@ast
Barbara Lattanzi
@en
Barbara Lattanzi
@es
Barbara Lattanzi
@nl
type
label
Barbara Lattanzi
@ast
Barbara Lattanzi
@en
Barbara Lattanzi
@es
Barbara Lattanzi
@nl
prefLabel
Barbara Lattanzi
@ast
Barbara Lattanzi
@en
Barbara Lattanzi
@es
Barbara Lattanzi
@nl
P106
P1153
55508672100
P21
P31
P496
0000-0003-2685-6504